EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Inhaled Dry Powder of Antiviral Agents: A Promising Approach to Treating Respiratory Viral Pathogens

Tushar Saha, Zia Uddin Masum, Anik Biswas, Moushumi Afroza Mou, Sohag Ahmed, Tamal Saha

Viruses · 2025

DOI: 10.3390/v17020252 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Viruses, 2025. Verfasst von Tushar Saha und 5 weiteren Autor:innen. Beteiligte Einrichtung: Mastaplex Ltd., Centre for Innovation, University of Otago, Dunedin 9016, New Zealand. Hauptthemen laut MEDLINE: Antiviral Agents, Dry Powder Inhalers, Respiratory Tract Infections, Virus Diseases. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 127 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Inhaled dry powder formulations of antiviral agents represent a novel and potentially transformative approach to managing respiratory viral infections. Traditional antiviral therapies in the form of tablets or capsules often face limitations in terms of therapeutic activity, systemic side effects, and delayed onset of action. Dry powder inhalers (DPIs) provide a targeted delivery system, ensuring the direct administration of antivirals to the infection site, the respiratory tract, which potentially enhance therapeutic efficacy and minimize systemic exposure. This review explores the current state of inhaled dry powder antiviral agents, their advantages over traditional routes, and specific formulations under development. We discuss the benefits of targeted delivery, such as improved drug deposition in the lungs and reduced side effects, alongside considerations related to the formulation preparation. In addition, we summarize the developed (published and marketed) inhaled dry powders of antiviral agents.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antiviral AgentsDry Powder InhalersRespiratory Tract InfectionsVirus DiseasesHumansAdministration, InhalationPowdersAnimalsDrug Delivery Systems

Stichwörter der Autor:innen

antiviraldry powderinfectionspathogensrespiratory

Substanzen

Antiviral AgentsPowders

Autor:innen und Institutionen

  • Mastaplex Ltd., Centre for Innovation, University of Otago, Dunedin 9016, New Zealand.
  • College of Pharmacy and Health Sciences, St. John's University, Queens, New York, NY 11439, USA.
  • Materials and Nanotechnology, North Dakota State University, Fargo, ND 58105, USA.
  • Department of Biological Science, St. John's University, Queens, New York, NY 11439, USA.
  • Department of Chemistry, West Virginia University, Morgantown, WV 26506, USA.
  • International Centre for Diarrheal Disease Research, Bangladesh, Dhaka 1212, Bangladesh.

Zitieren

APA

Saha, T., Masum, Z. U., Biswas, A., Mou, M. A., Ahmed, S., & Saha, T. (2025). Inhaled Dry Powder of Antiviral Agents: A Promising Approach to Treating Respiratory Viral Pathogens. Viruses. https://doi.org/10.3390/v17020252

Vancouver

Saha T, Masum ZU, Biswas A, Mou MA, Ahmed S, Saha T. Inhaled Dry Powder of Antiviral Agents: A Promising Approach to Treating Respiratory Viral Pathogens. Viruses. 2025. doi:10.3390/v17020252

BibTeX
@article{Saha2025,
  author = {Saha, Tushar and Masum, Zia Uddin and Biswas, Anik and Mou, Moushumi Afroza and Ahmed, Sohag and Saha, Tamal},
  title = {Inhaled Dry Powder of Antiviral Agents: A Promising Approach to Treating Respiratory Viral Pathogens},
  journal = {Viruses},
  year = {2025},
  doi = {10.3390/v17020252}
}
Kostenlos starten →